Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. One equities research analyst has rated the stock with a Buy rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Oramed Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ:ORMP opened at $4.00 on Friday. The company has a market capitalization of $166.40 million, a price-to-earnings ratio of 0.97 and a beta of 1.31. Oramed Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $5.47. The firm has a 50 day moving average of $4.44 and a 200 day moving average of $4.04.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). On average, sell-side analysts expect that Oramed Pharmaceuticals will post 1.47 EPS for the current year.

Insider Activity

In other news, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the transaction, the chief financial officer owned 861,076 shares of the company’s stock, valued at $3,883,452.76. The trade was a 2.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the completion of the transaction, the chief operating officer directly owned 1,328,130 shares in the company, valued at approximately $5,989,866.30. The trade was a 2.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hillsdale Investment Management Inc. acquired a new stake in Oramed Pharmaceuticals in the first quarter valued at approximately $331,000. Bank of New York Mellon Corp acquired a new position in shares of Oramed Pharmaceuticals during the second quarter worth $381,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Oramed Pharmaceuticals during the first quarter worth $63,000. BML Capital Management LLC increased its position in shares of Oramed Pharmaceuticals by 2.1% during the third quarter. BML Capital Management LLC now owns 884,392 shares of the biotechnology company’s stock worth $4,130,000 after purchasing an additional 18,123 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new position in shares of Oramed Pharmaceuticals during the second quarter worth $61,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.